About Us: Funds
MPM BioVentures I
(BB BioVentures, MPM BioVentures Parallel Fund)
The $230 million MPM BioVentures I family of funds was raised in 1997. The fund is now fully committed with 75% of the investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio is comprised of 26 companies with investments ranging from $5 - $20 million in each portfolio company. Within biotechnology, our investments are split between companies focused on therapeutics and enabling technologies. Roughly 80% of the funds were invested in U.S. companies, 20% in European companies.
MPM BioVentures II
The $600 million MPM BioVentures II family of funds -- which closed in the first quarter of 2000 – is comprised of a portfolio of investments in biotechnology, medical devices, and other healthcare-related fields. MPM BioVentures II has invested in 35 companies, with investments ranging from $10 - $50 million per company. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. Eighty five percent of the investments are in U.S. companies, and 15% are in European and Asian companies.
MPM BioVentures III
MPM closed its third venture initiative, the MPM BioVentures III Fund, in December 2002 with committed capital of $949 million. The MPM BioVentures III Fund has a portfolio of 39 companies, 85% focused on biotechnology and pharmaceutical products and 15% focused on medical devices and the life science tool segment. Its balanced portfolio of early, mid- and late-stage companies includes investments in public companies via PIPE transactions. About 95% of the capital was invested in U.S. companies, 5% in European companies.
MPM BioVentures IV
MPM Capital began investing its fourth venture initiative, the MPM BioVentures IV family of funds ("BV4"), during the second quarter of 2006. With committed capital of $552 million, BV4 has a portfolio of 23 companies with investments ranging from $5 million - $35 million. Approximately 75% of BV4's investments are focused on biotechnology and pharmaceutical products and 25% are focused on medical device companies. From a geographic perspective, approximately 20% of BV4's investments have been made outside the U.S., including investments in Asia as well as in Europe.
MPM BioVentures V
MPM Capital closed its fifth venture initiative, the MPM BioVentures V family of funds ("BV5") in 2010. With committed capital just under $300 million, BV5 has a portfolio of 6 companies currently. MPM is actively building the BV5 portfolio and is seeking innovative healthcare opportunities in the U.S. and abroad.